论文部分内容阅读
目的:观察抗乙肝免疫核糖核酸(Anti-HB-iRNA)联合病毒唑治疗慢性乙型肝炎的疗效。方法:132例符合诊断病例随机分两组,治疗组72例Anti-HB-iRNA3～4mg,肌注,隔日一次,1月后每周二次,病毒性15mg(kg·d)分三次口服。3个月为一疗程;对照组60例单用Anti-HB-iRNA,用法用量及疗程同治疗组。观察两组治疗前后谷丙转氨酶(ALT)恢复情况、治疗前后及治疗后6个月乙肝血清标志物阴转率。结果:Anti-HB-iRNA联合病毒唑有促ALT恢复及HBsAg、HBeAg阴转的作用,其疗效明显优于对照组(P<0.05),尤其是促HBeAg阴转效果较对照组差异有非常显著意义(P<0.01)。结论:Anti-HB-iRNA联合病毒唑是治疗慢性乙型肝炎的良好方案。
Objective: To observe the curative effect of anti-HB-iRNA and ribavirin on chronic hepatitis B patients. Methods: One hundred and thirty-two patients were randomly divided into two groups. Anti-HB-iRNA3 ~ 4mg was given to 72 patients in the treatment group, intramuscularly, once every other day and twice a week after January. The viral dose was 15mg (kg · d) orally three times. 3 months for a course of treatment; control group of 60 cases with Anti-HB-iRNA, dosage and course of treatment with the treatment group. The recovery of alanine aminotransferase (ALT) before and after treatment was observed in two groups. The negative conversion rate of serum HBV markers before and after treatment and after 6 months of treatment were observed. Results: Anti-HB-iRNA combined with ribavirin had the effect of promoting the recovery of ALT and HBsAg and HBeAg negative conversion, and the curative effect was obviously better than that of the control group (P <0.05). Especially, the anti-HB- Significance (P <0.01). Conclusion: Anti-HB-iRNA combined with ribavirin is a good treatment for chronic hepatitis B.